Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT06225622
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT06210360
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06197438
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 173
- Registration Number
- NCT06184698
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Safety and Efficacy of Thermosensitive Hydroxybutyl Chitosan and 5-fluorouracil Assisted Endoscopic Dacryocystorhinostomy in the Treatment of Chronic Dacryocystitis
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Tianjin Medical University Eye Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT06175676
- Locations
- 🇨🇳
Limin Zhu, Tianjin, China
The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- University of Aleppo
- Target Recruit Count
- 40
- Registration Number
- NCT06150144
- Locations
- 🇸🇾
Ibrahim Arnaout, Aleppo, Syrian Arab Republic
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06139211
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 206
- Registration Number
- NCT06107413
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven /ID# 257079, Leuven, Vlaams-Brabant, Belgium
🇺🇸Highlands Oncology Group, PA /ID# 259424, Springdale, Arkansas, United States
🇺🇸City of Hope National Medical Center /ID# 257576, Duarte, California, United States
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 272
- Registration Number
- NCT06102395
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.